TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection

Open Angle Glaucoma Clinical Trial

Official title:

A Single-center, Open Label, Prospective Study Assessing the IOP (Intraocular Pressure) Patterns Using SENSIMED Triggerfish® in Association With Anti-VEGF Injection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01983579
• Other study ID #: TF-1304
• Status: Terminated
• Phase: Phase 4
• First received: October 24, 2013
• Last updated: November 16, 2015
• Start date: October 2013
• Est. completion date: February 2014

Study information

• Verified date: November 2015
• Source: Sensimed AG
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Comité Ético de Investigación Clínica
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration). The study will be proposed to patients with AMD and patients with AMD and concomitant open angle glaucoma (OAG).

The study will be conducted in two stages. In both stages, patients will remain ambulatory and will be encouraged to follow a schedule as close to their usual lifestyle as possible, with the exception of particular activities such as caffeine intake, playing wind instruments, yoga and strenuous exercise. A patient diary will be distributed for the capture of patient activities during the TF pattern recording. Upon completion of each session, the CLS (contact lens sensor) will be removed and a final ophthalmic examination will be conducted.

In the first stage of the study, 20 patients with neovascular AMD with an IOP in the normal range and no concomitant glaucoma will be recruited. After having signed and dated the patient informed consent form, patients will undergo an initial ophthalmic examination. One eye will be selected for the study. If both eyes are eligible, the study eye will be selected in random manner.

All 20 AMD patients will receive two 24-hour recording sessions (S) with the TF CLS, at monthly interval. In the first session (S1) anti-VEGF injection will be carried out according to the study center standard protocol. For the second 24-hour TF recording session (S2), patients will be randomly distributed into three groups. Group A, consisting of 5 patients, will receive anti-VEGF injection with a different anti-VEGF substance as compared to S1. Group B, also consisting of 5 patients, will receive anti-VEGF without sclerotomy occlusion after injection as compared to S1. Finally, group C, including 10 patients, will receive anti-VEGF in a different dose (injection volume) as compared to S1. The randomization ratio between groups A, B and C is 1:1:2.

The overall study duration for an eligible patient in the first stage of this study is limited to 5 weeks.

If in the first stage of this study an injection protocol is identified that provokes significantly lesser elevation on the TF pattern, the alternative injection protocol will be evaluated against the current standard protocol. For the second stage, 30 patients of whom 15 with neovascular AMD and 15 with neovascular AMD and concomitant OAG will be recruited. After giving informed consent and confirmation of eligibility, all patients will receive two 24-hour TF CLS recording sessions (S3 and S4) at monthly interval, during which anti-VEGF injection according to the standard and alternative protocol will be carried out in random sequence.

The overall study duration for a patient in the second stage of the study is limited to 5 weeks.

The study has been planned to recruit 20 eligible patients in the first stage within 12 weeks from the date of initiation. The second stage will recruit 30 patients within 16 weeks. Hence the overall study duration from the first patient accrued into the study until last patient out equates to about 33 weeks. Allowing for a database lock within 4 weeks of study completion, a preliminary statistical report on the primary efficacy endpoint is foreseen within 2 weeks thereafter.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: February 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years to 99 Years

Eligibility

Inclusion Criteria:

• Diagnosis of neovascular AMD or neovascular AMD with concomitant OAG

• For neovascular AMD patients, IOP <21 mmHg, normal RNFL (retinal nerve fiber layer) thickness and optic disc, in need of treatment with monthly anti-VEGF injections and with best-corrected Snellen visual acuity of 0.5 or better on the non-study eye

• For OAG patients, open angle, with typical glaucomatous optic disc including diffuse or localized neuroretinal rim loss, excavation, and retinal nerve fiber layer defects, or repeated abnormal visual field defined as a pattern standard deviation outside of the 95% normal confidence limits or a Glaucoma Hemifield Test result outside normal limits

• For OAG patients any IOP-lowering treatment should be unchanged since at least 4 weeks at study entry and remain stable throughout the study

• Aged = 50 years

• Not more than 6 diopters spherical refraction equivalent in the study eye

• Having given written informed consent, prior to any investigational procedures

Exclusion Criteria:

• Pigmentary glaucoma, exfoliative glaucoma, narrow or closed iridocorneal angle or any other concomitant ocular conditions (except cataract) in the study eye

• History of ocular incision or laser surgery on the study eye (except cataract extraction)

• Corneal or conjunctival abnormality in the study eye precluding contact lens adaptation

• Severe dry eye syndrome

• Subjects with irregular sleep schedule or with sleep apnea syndrome

• Subjects allergic to silicone

• Subjects not able to understand the character and individual consequences of the investigation

• Participation in other clinical research within the last 4 weeks

• Any other contra-indication listed in the TF user manual

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Glaucoma, Open-Angle
• Macular Degeneration
• Neovascular Age Related Macular Degeneration (AMD)
• Open Angle Glaucoma
• Wet Macular Degeneration

Intervention

Procedure:
• Intraocular anti-VEGF injection

Device:
• SENSIMED Triggerfish

Locations

Country	Name	City	State
Spain	Hospital Univeristario y Politecnico La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Sensimed AG

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak amplitude on SENSIMED Trggerfish (TF) pattern within 2 hours of injection	The TF output before injection will be compared to the TF peak value recorded within 2 hours of the anti-VEGF injection. The difference between these two values is the peak amplitude, expressed in mVeq (millivolt equivalent).	2 hours after anti-VEGF injection	Yes